Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,306,937
  • Shares Outstanding, K 77,052
  • Annual Sales, $ 154,600 K
  • Annual Income, $ -44,200 K
  • 60-Month Beta 1.60
  • Price/Sales 3.59
  • Price/Cash Flow 230.71
  • Price/Book 2.58
Trade MYGN with:

Options Overview

Details
  • Implied Volatility 59.62%
  • Historical Volatility 32.61%
  • IV Percentile 3%
  • IV Rank 9.92%
  • IV High 109.94% on 04/19/21
  • IV Low 54.08% on 11/20/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 48
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 3,055
  • Open Int (30-Day) 3,226

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.27
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.08 +14.88%
on 05/17/21
30.58 -2.03%
on 06/14/21
+2.58 (+9.42%)
since 05/14/21
3-Month
24.54 +22.09%
on 05/11/21
33.97 -11.80%
on 04/06/21
-1.02 (-3.29%)
since 03/15/21
52-Week
10.54 +184.25%
on 06/25/20
33.97 -11.80%
on 04/06/21
+17.25 (+135.72%)
since 06/15/20

Most Recent Stories

More News
Predictive Genetic Testing & Consumer/Wellness Genomics Market Size to Reach USD 12.8 Billion in 2028: Reports and Data

Increasing awareness about utilization of genetic tests and integration of predictive genetic testing with advanced technology are factors expected to drive market growth.

ILMN : 451.81 (-0.07%)
MYGN : 29.96 (+0.07%)
Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company's transformation plan and growth initiatives during a fireside...

MYGN : 29.96 (+0.07%)
Why Is Myriad (MYGN) Down 11.5% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MYGN : 29.96 (+0.07%)
Myriad Genetics (MYGN) Sells myPath to Focus on Core Units

Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.

COO : 376.87 (+0.09%)
MYGN : 29.96 (+0.07%)
LH : 260.43 (+0.23%)
ASXC : 3.42 (-0.29%)
Myriad Genetics Completes the Sale of Myriad myPath(R) Melanoma, LLC, Laboratory to Castle Biosciences

On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory...

MYGN : 29.96 (+0.07%)
Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM

Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.

COO : 376.87 (+0.09%)
MYGN : 29.96 (+0.07%)
EYE : 47.81 (-1.97%)
NVST : 44.25 (+1.72%)
IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

, /PRNewswire/ -- (IPM), a leading pharmacy benefits management (PBM) company, now offers pharmacogenomics testing for patients suffering from depression or anxiety. The GeneSight® test, offered through...

MYGN : 29.96 (+0.07%)
Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval

Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.

BDX : 241.44 (-0.53%)
HOLX : 62.46 (-1.47%)
MYGN : 29.96 (+0.07%)
EXAS : 122.57 (-1.95%)
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q Solutions, a leading global...

MYGN : 29.96 (+0.07%)
Prostate Cancer Diagnostics Market Size, Share, Trends, Analysis and Forecast 2027

The report on Prostate Cancer Diagnostics provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

DXD.VN : 0.040 (unch)
BIOC : 4.38 (-4.16%)
CGIX : 4.61 (-2.33%)
FMI : 136.95 (-0.04%)
GHDX : 63.44 (-0.69%)
MYGN : 29.96 (+0.07%)
OPK : 3.69 (+1.65%)
SIEGY : 84.3700 (+2.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

3rd Resistance Point 30.90
2nd Resistance Point 30.56
1st Resistance Point 30.26
Last Price 29.96
1st Support Level 29.62
2nd Support Level 29.28
3rd Support Level 28.98

See More

52-Week High 33.97
Last Price 29.96
Fibonacci 61.8% 25.02
Fibonacci 50% 22.26
Fibonacci 38.2% 19.49
52-Week Low 10.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar